Company Description
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally.
The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community.
In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits.
Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E.
coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups.
Additionally, the company offers human medical point-of-care products and laboratory diagnostics services.
The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers.
IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
| Country | United States |
| Founded | 1983 |
| IPO Date | Jun 21, 1991 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 11,000 |
| CEO | Jonathan Mazelsky |
Contact Details
Address: One IDEXX Drive Westbrook, Maine 04092 United States | |
| Phone | 207 556 0300 |
| Website | idexx.com |
Stock Details
| Ticker Symbol | IDXX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000874716 |
| CUSIP Number | 45168D104 |
| ISIN Number | US45168D1046 |
| Employer ID | 01-0393723 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Jonathan J. Mazelsky | President, Chief Executive Officer and Director |
| Brian P. McKeon | Chief Financial Officer, Executive Vice President and Treasurer |
| Michael J. Lane | Executive Vice President and GM of Reference Laboratories and Information Technology |
| John Hart | Senior Vice President of Global Operations |
| Jeffery D. Chadbourne | Senior Vice President of Commercial Finance and Sales Operations |
| Dr. Martin Smith Ph.D. | Executive Vice President and Chief Technology Officer |
| Ken Grady | Senior Vice President and Chief Information Officer |
| Michael P. Johnson | Executive Vice President and Chief Human Resources Officer |
| George J. Fennell | Senior Vice President and Chief Revenue Officer |
| Michael Erickson Ph.D. | Executive Vice President and GM of Point of Care Diagnostics and Telemedicine |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 21, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 6, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Oct 31, 2024 | 8-K/A | [Amend] Current report |
| Oct 31, 2024 | 8-K | Current Report |
| Sep 6, 2024 | 144 | Filing |
| Aug 6, 2024 | 10-Q | Quarterly Report |